TELUS Digital reports first quarter 2025 results, with revenue and profitability in line with expectations; management reiterates 2025 outlook
VANCOUVER, British Columbia–(BUSINESS WIRE)–TELUS Digital Experience (TELUS Digital) (NYSE and TSX: TIXT), a leading global technology company specializing... Read more.
CPAC Systems AB Announces Strategic Minority Investment in Flying Fish
Accelerating the shift toward sustainable and intelligent water mobility GOTHENBURG, Sweden–(BUSINESS WIRE)–CPAC Systems AB, a leader in advanced control... Read more.
Algonquin Power & Utilities Corp. Announces 2025 First Quarter Financial Results; Plans to Host Investor Update Call on June 3
OAKVILLE, Ontario–(BUSINESS WIRE)–Algonquin Power & Utilities Corp. (TSX/NYSE: AQN) (“AQN” or the “Company”) announced today financial results... Read more.
Algonquin Power & Utilities Corp. Declares Second Quarter 2025 Common Share Dividend of U.S.$0.0650 (C$0.0897), and Declares Second Quarter 2025 Preferred Share Dividends
OAKVILLE, Ontario–(BUSINESS WIRE)–Algonquin Power & Utilities Corp. (“AQN”) (TSX: AQN, AQN.PR.A, AQN.PR.D, NYSE: AQN) announced today that its... Read more.
Essent Group Ltd. Announces First Quarter 2025 Results and Declares Quarterly Dividend
HAMILTON, Bermuda–(BUSINESS WIRE)–Essent Group Ltd. (NYSE: ESNT) today reported net income for the quarter ended March 31, 2025 of $175.4 million or... Read more.
Teletrac Navman’s Asset Trackers Honored as a 2025 Concrete Contractor Top Products Award Winner
NORTHBROOK, Ill.–(BUSINESS WIRE)–Teletrac Navman, a leading connected mobility platform and Vontier company, today announces that Teletrac Navman Asset... Read more.
Vir Biotechnology Announces Preliminary 24-Week Post-End of Treatment Data for Tobevibart and Elebsiran Combinations in Chronic Hepatitis B From the MARCH Study
HBsAg loss 24 weeks post-end of treatment achieved in 17% and 21% of participants with low baseline HBsAg receiving tobevibart + elebsiran without or with PEG-IFNα,... Read more.
Docebo Reports First Quarter 2025 Results
TORONTO–(BUSINESS WIRE)–Docebo Inc. (NASDAQ: DCBO; TSX:DCBO) (“Docebo” or the “Company”), a leading learning platform provider with a foundation... Read more.
LEO Pharma announces Positive Topline Phase 2b Results for Temtokibart in Moderate-to-Severe Atopic Dermatitis
Temtokibart achieved positive results for the primary endpoint for the 3 highest doses in a phase 2b clinical trial in adults with moderate-to-severe atopic dermatitis... Read more.
American Strategic Investment Co. Announces First Quarter 2025 Results
Company to Host Investor Webcast and Conference Call Today at 11:00 AM ET NEW YORK–(BUSINESS WIRE)–American Strategic Investment Co. (NYSE: NYC) (“ASIC”... Read more.